Compounds > rosiglitazone
Page last updated: 2024-08-25

rosiglitazone and Carcinoma

rosiglitazone has been researched along with Carcinoma in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (57.14)29.6817
2010's3 (42.86)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chen, J; Hahn, SS; Tang, Q; Wu, J; Zhao, S; Zheng, F1
Antonelli, A; Basolo, F; Berti, P; Fallahi, P; Ferrannini, E; Ferrari, SM; Marchetti, I; Materazzi, G; Miccoli, P; Ugolini, C1
Antonelli, A; Barani, L; Basolo, F; Berti, P; Fallahi, P; Ferrannini, E; Ferrari, SM; Giannini, R; Marchetti, I; Materazzi, G; Miccoli, P; Minuto, M1
Cantini, G; Ercolino, T; Francalanci, M; Gelmini, S; Lombardi, A; Luconi, M; Mangoni, M; Mannelli, M; Nesi, G; Orlando, C; Pepi, M; Poli, G; Pratesi, N; Serio, M1
Hu, JF; Li, GQ; Su, Q; Xiao, X; Zhang, L1
Aiello, A; Belfiore, A; Conte, E; Frasca, F; Genua, M; Murabito, A; Pandini, G; Sacco, A; Vigneri, R1
Blay, J; Lowthers, EL; Richard, CL1

Other Studies

7 other study(ies) available for rosiglitazone and Carcinoma

ArticleYear
Repression of integrin-linked kinase by antidiabetes drugs through cross-talk of PPARγ- and AMPKα-dependent signaling: role of AP-2α and Sp1.
    Cellular signalling, 2014, Volume: 26, Issue:3

    Topics: AMP-Activated Protein Kinases; Carcinoma; Cell Line, Tumor; Cell Proliferation; Cell Survival; Gene Expression Regulation, Neoplastic; Humans; Hypoglycemic Agents; Metformin; Mutation; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; PPAR gamma; Promoter Regions, Genetic; Protein Serine-Threonine Kinases; RNA Interference; RNA, Small Interfering; Rosiglitazone; Signal Transduction; Sp1 Transcription Factor; Thiazolidinediones; Transcription Factor AP-2

2014
Evaluation of the sensitivity to chemotherapeutics or thiazolidinediones of primary anaplastic thyroid cancer cells obtained by fine-needle aspiration.
    European journal of endocrinology, 2008, Volume: 159, Issue:3

    Topics: Antineoplastic Agents; Biopsy, Fine-Needle; Carcinoma; Cell Proliferation; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Humans; Proto-Oncogene Proteins B-raf; Rosiglitazone; Thiazolidinediones; Thyroid Neoplasms; Tumor Cells, Cultured

2008
Thiazolidinediones and antiblastics in primary human anaplastic thyroid cancer cells.
    Clinical endocrinology, 2009, Volume: 70, Issue:6

    Topics: Carcinoma; Cell Proliferation; Growth Inhibitors; Humans; Pioglitazone; Rosiglitazone; Thiazolidinediones; Thyroid Neoplasms; Tumor Cells, Cultured

2009
Rosiglitazone impairs proliferation of human adrenocortical cancer: preclinical study in a xenograft mouse model.
    Endocrine-related cancer, 2010, Volume: 17, Issue:1

    Topics: Adrenal Cortex Neoplasms; Animals; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Humans; Hypoglycemic Agents; Mice; Mice, Nude; Rosiglitazone; Thiazolidinediones; Tumor Burden; Xenograft Model Antitumor Assays

2010
Rosiglitazone reverses mitomycin C resistance in human gastric cancer cells.
    The American journal of the medical sciences, 2012, Volume: 343, Issue:5

    Topics: Adaptor Proteins, Signal Transducing; Antibiotics, Antineoplastic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma; Cell Line, Tumor; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Humans; Hypoglycemic Agents; Inhibitor of Apoptosis Proteins; Mitomycin; Neoplasm Proteins; RNA, Messenger; Rosiglitazone; Stomach Neoplasms; Thiazolidinediones

2012
Peroxisomal proliferator-activated receptor-gamma agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells.
    Endocrinology, 2006, Volume: 147, Issue:9

    Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Carcinoma; Caspase 3; Caspase 7; Caspases; Cell Cycle; Cell Division; Cell Line, Tumor; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Epithelial Cells; Gene Expression; Humans; Insulin-Like Growth Factor I; Intracellular Signaling Peptides and Proteins; Luciferases; Mesoderm; Phosphorylation; PPAR gamma; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Retinoblastoma Protein; RNA, Small Interfering; Rosiglitazone; Thiazolidinediones; Thyroid Neoplasms; Transfection

2006
15-Deoxy-delta(12,14)-prostaglandin J(2) down-regulates CXCR4 on carcinoma cells through PPARgamma- and NFkappaB-mediated pathways.
    Experimental cell research, 2007, Oct-01, Volume: 313, Issue:16

    Topics: Animals; Carcinoma; Cell Line, Tumor; Cyclopentanes; Down-Regulation; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Mice; NF-kappa B; PPAR gamma; Prostaglandin D2; Receptors, CXCR4; Rosiglitazone; Thiazolidinediones; Time Factors

2007